Evidence map›Paper›PMID 38446830›Full record

ArticlePLoS computational biology2024

Using birth-death processes to infer tumor subpopulation structure from live-cell imaging drug screening data.

Chenyu Wu, Einar Bjarki Gunnarsson, Even Moa Myklebust, Alvaro Köhn-Luque, Dagim Shiferaw Tadele, Jorrit Martijn Enserink, Arnoldo Frigessi, Jasmine Foo, Kevin Leder

Abstract read
In one paragraph

Article in PLoS computational biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Chenyu WuDepartment of Industrial and Systems Engineering, University of Minnesota, Minneapolis, Minnesota, United States of America.
Einar Bjarki GunnarssonSchool of Mathematics, University of Minnesota, Minneapolis, Minnesota, United States of America.
Even Moa MyklebustOslo Centre for Biostatistics and Epidemiology, Faculty of Medicine, University of Oslo, Oslo, Norway.ORCID 0000-0002-8380-6370
Alvaro Köhn-LuqueOslo Centre for Biostatistics and Epidemiology, Faculty of Medicine, University of Oslo, Oslo, Norway.
Dagim Shiferaw TadeleDepartment of Molecular Cell Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.ORCID 0000-0001-8319-678X
Jorrit Martijn EnserinkDepartment of Molecular Cell Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
Arnoldo FrigessiOslo Centre for Biostatistics and Epidemiology, Faculty of Medicine, University of Oslo, Oslo, Norway.
Jasmine FooSchool of Mathematics, University of Minnesota, Minneapolis, Minnesota, United States of America.
Kevin LederDepartment of Industrial and Systems Engineering, University of Minnesota, Minneapolis, Minnesota, United States of America.

Funding

A microengineered colon cancer-chip designed to investigate tumor-stromal interactions driving cancer progressionR01CA241137 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI MUMENTHALER, SHANNON MICHELLE · 2021 to 2025
$2.3M
NCI NIH HHS R01 CA241137
6 · The paper itself

Abstract

Tumor heterogeneity is a complex and widely recognized trait that poses significant challenges in developing effective cancer therapies. In particular, many tumors harbor a variety of subpopulations with distinct therapeutic response characteristics. Characterizing this heterogeneity by determining the subpopulation structure within a tumor enables more precise and successful treatment strategies. In our prior work, we developed PhenoPop, a computational framework for unravelling the drug-response subpopulation structure within a tumor from bulk high-throughput drug screening data. However, the deterministic nature of the underlying models driving PhenoPop restricts the model fit and the information it can extract from the data. As an advancement, we propose a stochastic model based on the linear birth-death process to address this limitation. Our model can formulate a dynamic variance along the horizon of the experiment so that the model uses more information from the data to provide a more robust estimation. In addition, the newly proposed model can be readily adapted to situations where the experimental data exhibits a positive time correlation. We test our model on simulated data (in silico) and experimental data (in vitro), which supports our argument about its advantages.

Indexed as

Genetic PhenomenaNeoplasmsDrug Evaluation, PreclinicalHumans

Identifiers

PMID38446830
PMCPMC10947663

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.